Soy Protein in the Management of Hyperlipidemia

Costa, Rebecca; Summa, Maria A.

doi:10.1345/aph.19371

Cited by 15 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have provided evidence that phytoestrogens in general can modulate plasma lipid and lipoprotein concentrations, but the data are not entirely consistent (Anderson et al, 1995). A recent overview concluded that soy could improve blood lipid parameters in both normocholesterolaemic and hypercholesterolaemic subjects, although the use of soy alone may not allow patients with hyperlipidaemia to achieve target lipid parameters (Costa & Summa, 2000). Soy, with which most of the studies have been carried out, has a variety of properties unrelated to isoflavone content that may contribute to its lipid-modulating properties (Potter, 1995).…”

Section: Discussionmentioning

confidence: 99%

Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study

et al. 2003

View full text Add to dashboard Cite

Background: Isoflavones are estrogen-like plant compounds that may protect against cardiovascular disease and endocrineresponsive cancer. Isoflavones may, because of their ability to act as selective estrogen receptor modulators, alter insulin-like growth factor (IGF) status. Objective: The aim of this study was to assess the effect of 1-month isoflavone supplementation (86 mg/day red clover-derived isoflavones) on IGF status. Design and subjects: Healthy pre-(n ¼ 16) and postmenopausal (n ¼ 7) women were invited to take part in a randomised, placebo-controlled crossover study with a minimum 2-month washout period. Results: For premenopausal subjects, the change in IGF-1, IGF-BP1 and IGF-BP3 assessed at different points of the menstrual cycle did not differ between isoflavone and placebo phase. However, the change in IGF-1, when examined pre-and postsupplementation, was nonsignificantly reduced (P ¼ 0.06) on the isoflavone supplement compared to placebo. For postmenopausal subjects, the change in IGF-1, IGF-BP1 and IGFBP-3 concentrations over the supplementation period did not differ between isoflavone or placebo phase. Isoflavones increased HDL in postmenopausal women compared to placebo (P ¼ 0.02) but did not alter either cholesterol or triacylglycerol concentrations, and had no effect on antioxidant status. Conclusions: This study shows that 1-month supplementation with red clover isoflavones has a positive effect on HDL cholesterol, but at most a small effect on IGF status in premenopausal and no effect in postmenopausal subjects. Further studies are required to ascertain the role these dietary compounds may have to play in breast cancer prevention. Sponsorhip: The isoflavone and placebo supplements were kindly supplied by Novogen (North Ryde, Sydney, Australia). This study was supported by Action Against Breast Cancer registered charity number 1020967.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Solvents, phosphate-buffered saline (PBS) and Dulbecco's modified Eagle's medium (DMEM) were purchased from SigmaAldrich Co. (Milan, Italy). [2][3][4][5][6][7][8][9][10][11][12][13][14] C]Acetate (50 mCi/mM) was obtained from Amersham Pharmacia Biotech (UK). Analytical thin-layer chromatography (TLC) was carried out using Alufolien Kieselgel 60F254 plates from Merck (Darmstadt, Germany).…”

Section: Methodsmentioning

confidence: 99%

“…This benefit, mainly due to a lowering of serum cholesterol, and of low-density lipoprotein (LDL)-cholesterol in particular [2], has been confirmed and possibly traced to one of the major soybean proteins [3]. Recent studies suggested, however, that only about a quarter of the cholesterol-lowering effect of soy could be attributed to its protein content, the rest deriving from the presence in the bean of other bioactive compounds [4].…”

Section: Introductionmentioning

confidence: 99%

Soybean germ oil inhibits oxidosqualene cyclase in 3T3 fibroblasts

Cravotto

Robaldo

Binello

et al. 2005

Eur. J. Lipid Sci. Technol.

View full text Add to dashboard Cite

Soybean germ oil (SGO) could take an important place among nutraceuticals if the finding were confirmed that a daily intake of SGO helps to maintain a normal level of serum cholesterol. Adapting the rice milling technology to the soybean refining process, we achieved a rapid and efficient separation of soybean bran and cotyledon from the hypocotyle. Our soybean germ was no less than 95% hypocotyle. SGO obtained from it by typical hexane extraction was very rich in tocopherols (total content 4.35 g/kg) and phytosterols (b-sitosterol 57.4%, D-7-stigmastenol 20.2%, D-7-avenasterol 6.8%, stigmasterol 6.2%, campesterol 5.4%, D-7-campesterol 1.2%, D-5-avenasterol 0.95%, etc.; total sterols 44.3 g/kg). The most prominent fatty acids were linoleic (56.2%), linolenic (15.5%) and oleic acid (10.6%). Although isoflavones abound in soybean germ (17.7 g/kg), only traces of them passed into the hexane extract (7 mg/kg). In murine 3T3 fibroblasts, SGO was found to reduce the incorporation of [ 14 C]acetate into sterols, by inhibiting oxidosqualene cyclase.

show abstract

“…Specifically, the case of soybeansis mentioned, both recommended by the Food and Drug Administration (FDA) and the American Heart Association (AHA),because by consuming 25 g/day of this protein as part of a diet low in saturated fat there is a decrease in cholesterol levels. An estimated consumption amount of protein decrease lipoprotein LDL up to 8% in patients with high cholesterol levels, while it has no adverse effects in people with normal cholesterol levels 53 .…”

Section: Bioactive Peptidesmentioning

confidence: 99%